Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Phloroglucinol
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CinPhloro Doses First Participant In Phase 2 Enviva Study Of CIN-103 For IBS-D
Details : CIN-103 (phloroglucinol) is a voltage-gated calcium channel blocker. It is being evaluated as a new approach for the chronic treatment of irritable bowel syndrome with predominant diarrhea (IBS-D).
Brand Name : CIN-103
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 22, 2024
Lead Product(s) : Phloroglucinol
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?